Causal effect of lipoprotein(a) level on chronic kidney disease of European ancestry: a two-sample Mendelian randomization study

References

• Drawz P, Rahman M. Chronic kidney disease. Ann Intern Med. 2015;162(11):ITC1–IT16. doi: 10.7326/AITC201506020.
   PubMed Web of Science ®Google Scholar
• GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–1544. doi: 10.1016/S0140-6736(16)31012-1.
   PubMed Web of Science ®Google Scholar
• Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765. doi: 10.1371/journal.pone.0158765.
   PubMed Web of Science ®Google Scholar
• Park S, Lee S, Kim Y, et al. Reduced risk for chronic kidney disease after recovery from metabolic syndrome: a nationwide population-based study. Kidney Res Clin Pract. 2020;39(2):180–191. doi: 10.23876/j.krcp.20.016.
   PubMed Web of Science ®Google Scholar
• Schmidt K, Noureen A, Kronenberg F, et al. Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016;57(8):1339–1359. doi: 10.1194/jlr.R067314.
   PubMed Web of Science ®Google Scholar
• Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692–711. doi: 10.1016/j.jacc.2016.11.042.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol. 2012;60(8):716–721. doi: 10.1016/j.jacc.2012.04.038.
   PubMed Web of Science ®Google Scholar
• Utermann G, Menzel HJ, Kraft HG, et al. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest. 1987;80(2):458–465. doi: 10.1172/JCI113093.
   PubMed Web of Science ®Google Scholar
• Berg K. A new serum type system in man–the Lp system. Acta Pathol Microbiol Scand. 1963;59:369–382. doi: 10.1111/j.1699-0463.1963.tb01808.x.
   PubMedGoogle Scholar
• Berglund L, Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol. 2004;24(12):2219–2226. doi: 10.1161/01.ATV.0000144010.55563.63.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57(11):1953–1975. doi: 10.1194/jlr.R071233.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–2853. doi: 10.1093/eurheartj/ehq386.
   PubMed Web of Science ®Google Scholar
• Liu M, Li X-C, Lu L, et al. Cardiovascular disease and its relationship with chronic kidney disease. Eur Rev Med Pharmacol Sci. 2014;18(19):2918–2926.
   PubMed Web of Science ®Google Scholar
• Catena C, Colussi G, Nait F, et al. Early renal failure as a cardiovascular disease: focus on lipoprotein(a) and prothrombotic state. World J Nephrol. 2015;4(3):374–378. doi: 10.5527/wjn.v4.i3.374.
   PubMedGoogle Scholar
• Kronenberg F, Kuen E, Ritz E, et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol. 2000;11(1):105–115. doi: 10.1681/ASN.V111105.
   PubMed Web of Science ®Google Scholar
• Uhlig K, Wang S-R, Beck GJ, et al. Factors associated with lipoprotein(a) in chronic kidney disease. Am J Kidney Dis. 2005;45(1):28–38. doi: 10.1053/j.ajkd.2004.08.043.
   PubMed Web of Science ®Google Scholar
• Albers JJ, Koschinsky ML, Marcovina SM. Evidence mounts for a role of the kidney in lipoprotein(a) catabolism. Kidney Int. 2007;71(10):961–962. doi: 10.1038/sj.ki.5002240.
   PubMed Web of Science ®Google Scholar
• Oida K, Takai H, Maeda H, et al. Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure. Clin Chem. 1992;38(11):2244–2248. doi: 10.1093/clinchem/38.11.2244.
   PubMed Web of Science ®Google Scholar
• Emdin CA, Khera AV, Natarajan P, et al. Phenotypic characterization of genetically lowered human Lipoprotein(a) levels. J Am Coll Cardiol. 2016;68(25):2761–2772. doi: 10.1016/j.jacc.2016.10.033.
   PubMed Web of Science ®Google Scholar
• Lawlor DA, Harbord RM, Sterne JAC, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27(8):1133–1163. doi: 10.1002/sim.3034.
   PubMed Web of Science ®Google Scholar
• Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89–R98. doi: 10.1093/hmg/ddu328.
   PubMed Web of Science ®Google Scholar
• Sekula P, Del Greco M F, Pattaro C, et al. Mendelian randomization as an approach to assess causality using observational data. J Am Soc Nephrol. 2016;27(11):3253–3265. doi: 10.1681/ASN.2016010098.
   PubMed Web of Science ®Google Scholar
• Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518–2528. doi: 10.1056/NEJMoa0902604.
   PubMed Web of Science ®Google Scholar
• Wuttke M, Li Y, Li M, et al. A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nat Genet. 2019;51(6):957–972. doi: 10.1038/s41588-019-0407-x.
   PubMed Web of Science ®Google Scholar
• Pan Y, Li H, Wang Y, et al. Causal effect of Lp(a) [Lipoprotein(a)] level on ischemic stroke and alzheimer disease: a Mendelian Randomization Study. Stroke. 2019;50(12):3532–3539. doi: 10.1161/STROKEAHA.119.026872.
   PubMed Web of Science ®Google Scholar
• Myers TA, Chanock SJ, Machiela MJ. An R package for rapidly calculating linkage disequilibrium statistics in diverse populations. Front Genet. 2020;11:157. doi: 10.3389/fgene.2020.00157.
   PubMed Web of Science ®Google Scholar
• Staley JR, Blackshaw J, Kamat MA, et al. PhenoScanner: a database of human genotype-phenotype associations. Bioinformatics. 2016;32(20):3207–3209. doi: 10.1093/bioinformatics/btw373.
   PubMed Web of Science ®Google Scholar
• Chen X, Kong J, Pan J, et al. Kidney damage causally affects the brain cortical structure: A Mendelian randomization study. eBioMedicine. 2021;72:103592. doi: 10.1016/j.ebiom.2021.103592.
   PubMed Web of Science ®Google Scholar
• Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512–525. doi: 10.1093/ije/dyv080.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343(jul22 1):d4002–d4002. doi: 10.1136/bmj.d4002.
   PubMed Web of Science ®Google Scholar
• Bowden J, Davey Smith G, Haycock PC, et al. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40(4):304–314. doi: 10.1002/gepi.21965.
   PubMed Web of Science ®Google Scholar
• Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32(5):377–389. doi: 10.1007/s10654-017-0255-x.
   PubMed Web of Science ®Google Scholar
• Hemani G, Zheng J, Elsworth B, et al. The MR-base platform supports systematic causal inference across the human phenome. Elife. 2018;7:7. doi: 10.7554/eLife.34408.
   Web of Science ®Google Scholar
• Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol. 2017;46(6):1734–1739. doi: 10.1093/ije/dyx034.
   PubMed Web of Science ®Google Scholar
• Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem. 2004;37(5):333–343. doi: 10.1016/j.clinbiochem.2003.12.007.
   PubMed Web of Science ®Google Scholar
• Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412–423. doi: 10.1001/jama.2009.1063.
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Astor BC, Longenecker JC, et al. Association of kidney function with serum Lipoprotein(a) level: the third national health and nutrition examination survey (1991-1994). Am J Kidney Dis. 2002;40(5):899–908. doi: 10.1053/ajkd.2002.36319.
   PubMed Web of Science ®Google Scholar
• Lin J, Reilly MP, Terembula K, et al. Plasma Lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria. PLoS One. 2014;9(12):e114397. doi: 10.1371/journal.pone.0114397.
   PubMed Web of Science ®Google Scholar
• Kronenberg F, König P, Neyer U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995;6(1):110–120. doi: 10.1681/ASN.V61110.
   PubMed Web of Science ®Google Scholar
• Shoji T, Nishizawa Y, Nishitani H, et al. High serum lipoprotein(a) concentrations in uremic patients treated with continuous ambulatory peritoneal dialysis. Clin Nephrol. 1992;38(5):271–276.
   PubMed Web of Science ®Google Scholar
• Aggarwal HK, Jain D, Lathar M, et al. Lipoprotein-A and carotid intima media thickness as cardiovascular risk factors in patients of chronic kidney disease. Ren Fail. 2010;32(6):647–652. doi: 10.3109/0886022X.2010.486097.
   PubMed Web of Science ®Google Scholar
• Frischmann ME, Kronenberg F, Trenkwalder E, et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int. 2007;71(10):1036–1043. doi: 10.1038/sj.ki.5002131.
   PubMed Web of Science ®Google Scholar
• Yun J-S, Ahn Y-B, Song K-H, et al. Lipoprotein(a) predicts a new onset of chronic kidney disease in people with Type 2 diabetes mellitus. Diabet Med. 2016;33(5):639–643. doi: 10.1111/dme.12862.
   PubMed Web of Science ®Google Scholar
• Kettunen J, Demirkan A, Würtz P, et al. Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. Nat Commun. 2016;7(1):11122. doi: 10.1038/ncomms11122.
   PubMedGoogle Scholar
• Jang AY, Han SH, Sohn IS, et al. Lipoprotein(a) and Cardiovascular Diseases- Revisited. Circ J. 2020;84(6):867–874. doi: 10.1253/circj.CJ-20-0051.
   PubMed Web of Science ®Google Scholar